Sec Form 4 Filing - Lloyd George W. @ Royalty Pharma plc - 2020-06-15

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Lloyd George W. 2. Issuer Name and Ticker or Trading Symbol Royalty Pharma plc [ RPRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) EVP, Investments & GC (Last) (First) (Middle) C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET 3. Date of Earliest Transaction (MM/DD/YY) 06/15/2020 (Street) NEW YORK, NY10022 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Ordinary Shares 06/18/2020 P 3,000 A $ 28 3,000 D Class A Ordinary Shares 06/18/2020 P 11,200 A $ 28 11,200 I By IRA Class A Ordinary Shares 06/18/2020 C( 1 )( 2 ) 262,760 A $ 0 ( 1 ) 273,960 I By IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares LP interests in RPI US Partners 2019, LP $ 0 06/15/2020 A( 3 ) 7,730 ( 4 ) ( 4 ) Class A Ordinary Shares 77,300 $ 0 7,730 ( 5 ) D LP interests in RPI US Partners 2019, LP $ 0 06/15/2020 A( 3 ) 83,638 ( 4 ) ( 4 ) Class A Ordinary Shares 836,380 $ 0 83,638 ( 6 ) I By GWL 2013 NG, LLC LP interests in RPI US Partners 2019, LP $ 0 06/15/2020 A( 3 ) 596,707 ( 4 ) ( 4 ) Class A Ordinary Shares 5,967,070 $ 0 596,707 ( 7 ) I By GWL 2014 G, LLC LP interests in RPI International Holdings 2019, LP $ 0 06/15/2020 A( 3 ) 28,326 ( 8 ) ( 8 ) Class A Ordinary Shares 283,260 $ 0 28,326 ( 9 ) I By IRA ICAI Interests $ 0 06/15/2020 A( 3 ) 353,000 ( 10 ) ( 10 ) Limited Partnership interests in RPI US Partners 2019, LP ( 4 ) 353,000 $ 0 353,000 I By GWL 2014 G, LLC LP interests in RPI International Holdings 2019, LP $ 0 ( 1 ) 06/18/2020 C( 1 )( 2 ) 26,276 ( 8 ) ( 8 ) Class A Ordinary Shares 262,760 $ 0 2,050 ( 9 ) I By IRA

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Lloyd George W. C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET NEW YORK, NY10022 EVP, Investments & GC Signatures /s/ Jason Mehar, as Attorney-in-Fact for George W. Lloyd 06/22/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. ( 2 )This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. ( 3 )The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. ( 4 )Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. ( 5 )Includes RPI US LP Interests convertible into 5,590 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. ( 6 )Includes RPI US LP Interests convertible into 60,520 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. ( 7 )Includes RPI US LP Interests convertible into 4,573,096 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances. ( 8 )Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. ( 9 )Includes RPI Intl. LP Interests convertible into 20,500 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. ( 10 )These ICAI Interests represent a grant of up to 353,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.